ArticleCell reports2019
An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma.
Abstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Human Papillomavirus Integration Induces Oncogenic Host Gene Fusions in Oropharyngeal Cancers.Cancer discovery · 2025Article
- Article
- Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONIC.Cell & bioscience · 2025Article
- Current challenges and potential opportunities for interception and prevention of head and neck cancer.Carcinogenesis · 2025Review
- Precision therapeutic targets for HPV-positive cancers: an overview and new insights.Infectious agents and cancer · 2025Review
- Engineering models of head and neck and oral cancers on-a-chip.Biomicrofluidics · 2024Review
- Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Review
- Inducible TgfbR1 and Pten deletion in a model of tongue carcinogenesis and chemoprevention.Cancer gene therapy · 2023Article
- HPV-positive murine oral squamous cell carcinoma: development and characterization of a new mouse tumor model for immunological studies.Journal of translational medicine · 2023Article
- PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.Biology · 2023Review
- Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.Cancer research communications · 2022Article
- Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer.International journal of molecular sciences · 2022Review
- Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer.Neoplasia (New York, N.Y.) · 2022Article
- Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis.Journal of immunology research · 2022Review
- Exposure to Microbial Metabolite Butyrate Prolongs the Survival Time and Changes the Growth Pattern of Human Papillomavirus 16 E6/E7-Immortalized Keratinocytes in Vivo.The American journal of pathology · 2021Article
- Lysyl hydroxylase 2-induced collagen cross-link switching promotes metastasis in head and neck squamous cell carcinomas.Neoplasia (New York, N.Y.) · 2021Article
- Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Miranda B CarperLineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Scott TroutmanDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA.
Bethany L WagnerGraduate Curriculum in Pathobiology and Translational Medicine, Biological & Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kevin M ByrdDepartment of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Graduate Curriculum in Oral & Craniofacial Biomedicine, Biological & Biomedical Sciences Program, UNC Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sara R SelitskyBioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kshitij Parag-SharmaGraduate Curriculum in Cell Biology and Physiology, Biological & Biomedical Sciences Program, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Erin C HenryDivision of Oral and Craniofacial Health Sciences, UNC Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Weimin LiDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Joel S ParkerBioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Genetics, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stephanie A MontgomeryDepartment of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
John L ClevelandDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Scott E WilliamsLineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joseph L KissilDepartment of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA.
David N HayesLineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medical Oncology, University of Tennessee Health Sciences West Cancer Center, Memphis, TN, USA.
Antonio L AmelioLineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Oral and Craniofacial Health Sciences, UNC Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Biomedical Research Imaging Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: antonio_amelio@unc.edu.
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MTraining Program for the Next Generation of Oral Health Researchers (NextGen)T90DE021986 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EVERETT, ERIC T. · 2011 to 2017
$2.3MDuke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2MConvergence of CREB and MYC Pathways in Oncogenesis.R00CA157954 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMELIO, ANTONIO LUIGI · 2014 to 2016
$740kTraining Program for the Next Generation of Oral Health Researches (NextGen)R90DE022527 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EVERETT, ERIC T. · 2011 to 2016
$672kMechanisms of Oral Epithelial DifferentiationK08DE026537 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BYRD, KEVIN MATTHEW · 2016 to 2020
$430kIlluminating the Role of Oral Stem Cells in the Development of Oral Squamous Cell CarcinomasR21DE025725 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMELIO, ANTONIO LUIGI, WILLIAMS, SCOTT E · 2016 to 2017
$418kNCI NIH HHS P30 CA016086NCI NIH HHS P30 CA076292NCI NIH HHS R00 CA157954NCI NIH HHS T32 CA211056NIDCR NIH HHS K08 DE026537NIDCR NIH HHS R21 DE025725NIDCR NIH HHS R90 DE022527NIDCR NIH HHS T90 DE021986NIEHS NIH HHS P30 ES010126
Abstract
The incidence of human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is increasing and implicated in more than 60% of all oropharyngeal carcinomas (OPSCCs). Although whole-genome, transcriptome, and proteome analyses have identified altered signaling pathways in HPV-induced HNSCCs, additional tools are needed to investigate the unique pathobiology of OPSCC. Herein, bioinformatics analyses of human HPV(+) HNSCCs revealed that all tumors express full-length E6 and identified molecular subtypes based on relative E6 and E7 expression levels. To recapitulate the levels, stoichiometric ratios, and anatomic location of E6/E7 expression, we generated a genetically engineered mouse model whereby balanced expression of E6/E7 is directed to the oropharyngeal epithelium. The addition of a mutant PIK3CA
Indexed as
Disease Models, AnimalAnimalsCarcinogenesisCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleGene ExpressionHead and Neck NeoplasmsHumansImmunocompetenceInternal Ribosome Entry SitesMaleMiceMice, Inbred C57BLMice, TransgenicNatural Killer T-CellsClass I Phosphatidylinositol 3-KinasesE6 protein, Human papillomavirus type 16Internal Ribosome Entry Sitesoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsPik3ca protein, mouseRepressor ProteinsGEMM, human papilloma virusgenetically engineered mouse modelhead and neck squamous cell carcinomaHNSCCHPVHPV16immunocompetentLumiFluoroncogeneOPSCCoropharyngeal squamous cell carcinomatumorigenesistumor suppressor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.